Efficacy of Tixagevimab-Cilgavimab as Immunoprophylaxis in Patients With Hematologic Cancer

JAMA Oncol. 2024 Mar 1;10(3):405-407. doi: 10.1001/jamaoncol.2023.6446.
No abstract available

Plain language summary

This cohort study compares outcomes for patients with hematologic malignant tumors who prophylactically received tixagevimab-cilgavimab against SARS-CoV-2 with those who did not.

MeSH terms

  • Antibodies, Monoclonal*
  • Hematologic Neoplasms* / complications
  • Hematologic Neoplasms* / drug therapy
  • Humans
  • Patients

Substances

  • tixagevimab
  • cilgavimab
  • Antibodies, Monoclonal